BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Xenon Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-13 8:20 pm Sale |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 1,271,243 2.000% |
-3,034,297 (-70.47%) |
Filing |
| 2022-03-18 7:18 pm Sale |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 4,305,540 8.200% |
-851,946 (-16.52%) |
Filing |
| 2022-02-14 1:53 pm Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 5,157,486 9.990% |
1,658,140 (+47.38%) |
Filing |
| 2021-02-12 6:52 pm Sale |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 3,499,346 10.000% |
-17,505 (-0.50%) |
Filing |
| 2020-06-22 5:17 pm Purchase |
2020-06-16 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 3,516,851 10.100% |
860,794 (+32.41%) |
Filing |